Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	fatty acyl-[ACP] hydrolase activity	OLAH FASN	2.65e-06	2	33	2	GO:0016297
GeneOntologyMolecularFunction	thiolester hydrolase activity	OLAH FASN	2.73e-03	47	33	2	GO:0016790
GeneOntologyMolecularFunction	extracellular matrix binding	DMP1 ZAN	6.47e-03	73	33	2	GO:0050840
GeneOntologyMolecularFunction	calcium ion binding	ADGRE4P HSPG2 FAT4 DMP1 DSG3	7.27e-03	749	33	5	GO:0005509
MousePheno	abnormal cartilaginous joint morphology	HSPG2 DMP1 DSG3 PKD1	1.23e-05	85	24	4	MP:0030875
MousePheno	abnormal vertebrae development	HSPG2 FAT4 PKD1	1.36e-04	59	24	3	MP:0005225
MousePheno	abnormal intervertebral disk morphology	HSPG2 DSG3 PKD1	1.98e-04	67	24	3	MP:0004173
MousePheno	abnormal symphysis morphology	HSPG2 DSG3 PKD1	2.35e-04	71	24	3	MP:0030877
MousePheno	abnormal bone mineralization	HSPG2 DMP1 PGD PKD1	2.36e-04	181	24	4	MP:0002896
MousePheno	abnormal synchondrosis	DMP1 PKD1	3.34e-04	16	24	2	MP:0004053
MousePheno	decreased chondrocyte proliferation	HSPG2 PKD1	3.34e-04	16	24	2	MP:0014101
MousePheno	abnormal conotruncal ridge morphology	HSPG2 PKD1	3.78e-04	17	24	2	MP:0010585
MousePheno	abnormal conotruncus morphology	HSPG2 PKD1	4.25e-04	18	24	2	MP:0010583
MousePheno	chondrodystrophy	HSPG2 PKD1	4.25e-04	18	24	2	MP:0002657
MousePheno	abnormal bone ossification	HSPG2 FAT4 DMP1 PGD PKD1	4.79e-04	395	24	5	MP:0008271
MousePheno	abnormal joint morphology	KLK12 HSPG2 DMP1 DSG3 PKD1	4.90e-04	397	24	5	MP:0002932
MousePheno	abnormal chondrocyte proliferation	HSPG2 PKD1	5.27e-04	20	24	2	MP:0014099
MousePheno	abnormal endochondral bone ossification	HSPG2 FAT4 PKD1	8.07e-04	108	24	3	MP:0008272
MousePheno	abnormal kidney cell proliferation	FAT4 PKD1	8.95e-04	26	24	2	MP:0011439
MousePheno	abnormal long bone hypertrophic chondrocyte zone	HSPG2 DMP1 PKD1	9.20e-04	113	24	3	MP:0000165
MousePheno	abnormal bone marrow cavity morphology	HSPG2 PKD1	9.66e-04	27	24	2	MP:0000065
MousePheno	abnormal laryngeal cartilage morphology	DSG3 PKD1	1.11e-03	29	24	2	MP:0002256
MousePheno	delayed bone ossification	HSPG2 DMP1 PKD1	1.29e-03	127	24	3	MP:0000060
MousePheno	abnormal pericardial cavity morphology	HSPG2 PKD1 MIB1	1.32e-03	128	24	3	MP:0012501
MousePheno	abnormal fibrous joint morphology	HSPG2 DSG3 PKD1	1.54e-03	135	24	3	MP:0030878
MousePheno	aneurysm	HSPG2 PKD1	1.62e-03	35	24	2	MP:0003279
MousePheno	increased diameter of long bones	HSPG2 DMP1	1.72e-03	36	24	2	MP:0008151
MousePheno	abnormal long bone metaphysis morphology	HSPG2 DMP1	2.01e-03	39	24	2	MP:0000133
Domain	Thioesterase	OLAH FASN	2.84e-06	2	32	2	PF00975
Domain	M_domain	TNRC6C TNRC6A	2.84e-06	2	32	2	PF12938
Domain	GW182_M_dom	TNRC6C TNRC6A	2.84e-06	2	32	2	IPR026805
Domain	Thioesterase	OLAH FASN	2.84e-06	2	32	2	IPR001031
Domain	Ago_hook	TNRC6C TNRC6A	8.52e-06	3	32	2	PF10427
Domain	TNRC6-PABC_bdg	TNRC6C TNRC6A	8.52e-06	3	32	2	PF16608
Domain	TNRC6_PABC-bd	TNRC6C TNRC6A	8.52e-06	3	32	2	IPR032226
Domain	Argonaute_hook_dom	TNRC6C TNRC6A	8.52e-06	3	32	2	IPR019486
Domain	SEA	MUC16 HSPG2	2.55e-04	14	32	2	SM00200
Domain	ConA-like_dom	HSPG2 FAT4 ZAN TRIM10	5.11e-04	219	32	4	IPR013320
Domain	SEA	MUC16 HSPG2	6.43e-04	22	32	2	PF01390
Domain	EGF_3	ADGRE4P HSPG2 FAT4 ZAN	6.66e-04	235	32	4	PS50026
Domain	EGF	ADGRE4P HSPG2 FAT4 ZAN	6.66e-04	235	32	4	SM00181
Domain	SEA	MUC16 HSPG2	7.04e-04	23	32	2	PS50024
Domain	SEA_dom	MUC16 HSPG2	7.04e-04	23	32	2	IPR000082
Domain	EGF-like_dom	ADGRE4P HSPG2 FAT4 ZAN	8.27e-04	249	32	4	IPR000742
Domain	-	CMBL OLAH FASN	1.09e-03	119	32	3	3.40.50.1820
Domain	AB_hydrolase	CMBL OLAH FASN	1.09e-03	119	32	3	IPR029058
Domain	EGF-like_Ca-bd_dom	ADGRE4P HSPG2 FAT4	1.23e-03	124	32	3	IPR001881
Domain	GPS	ADGRE4P PKD1	1.54e-03	34	32	2	SM00303
Domain	GPS	ADGRE4P PKD1	1.63e-03	35	32	2	PF01825
Domain	GPS	ADGRE4P PKD1	1.73e-03	36	32	2	PS50221
Domain	GPS	ADGRE4P PKD1	1.82e-03	37	32	2	IPR000203
Domain	LAM_G_DOMAIN	HSPG2 FAT4	1.92e-03	38	32	2	PS50025
Domain	Laminin_G_2	HSPG2 FAT4	2.13e-03	40	32	2	PF02210
Domain	LamG	HSPG2 FAT4	2.57e-03	44	32	2	SM00282
Domain	LDLRA_1	HSPG2 PKD1	3.05e-03	48	32	2	PS01209
Domain	NAD(P)-bd_dom	DDO FASN PGD	3.18e-03	173	32	3	IPR016040
Domain	LDLRA_2	HSPG2 PKD1	3.18e-03	49	32	2	PS50068
Domain	-	PAOX DDO	4.13e-03	56	32	2	3.50.50.60
Domain	FAD/NAD-binding_dom	PAOX DDO	4.28e-03	57	32	2	IPR023753
Domain	Laminin_G	HSPG2 FAT4	4.43e-03	58	32	2	IPR001791
Pathway	REACTOME_POST_TRANSCRIPTIONAL_SILENCING_BY_SMALL_RNAS	TNRC6C TNRC6A	7.38e-05	7	27	2	M46421
Pathway	REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING	FASN TNRC6C TNRC6A	9.61e-05	47	27	3	M29777
Pathway	REACTOME_REGULATION_OF_PTEN_MRNA_TRANSLATION	TNRC6C TNRC6A	1.26e-04	9	27	2	M27810
Pathway	REACTOME_REGULATION_OF_NPAS4_MRNA_TRANSLATION	TNRC6C TNRC6A	1.26e-04	9	27	2	M46436
Pathway	REACTOME_REGULATION_OF_CDH11_MRNA_TRANSLATION_BY_MICRORNAS	TNRC6C TNRC6A	1.57e-04	10	27	2	M48013
Pathway	REACTOME_REGULATION_OF_NPAS4_GENE_EXPRESSION	TNRC6C TNRC6A	2.72e-04	13	27	2	M46434
Pathway	REACTOME_REGULATION_OF_RUNX1_EXPRESSION_AND_ACTIVITY	TNRC6C TNRC6A	4.72e-04	17	27	2	M27788
Pathway	REACTOME_REGULATION_OF_MITF_M_DEPENDENT_GENES_INVOLVED_IN_APOPTOSIS	TNRC6C TNRC6A	5.92e-04	19	27	2	M48238
Pubmed	Crystal Structure and Substrate Specificity of Human Thioesterase 2: INSIGHTS INTO THE MOLECULAR BASIS FOR THE MODULATION OF FATTY ACID SYNTHASE.	OLAH FASN	9.28e-07	2	34	2	26663084
Pubmed	Impact of scaffolding protein TNRC6 paralogs on gene expression and splicing.	TNRC6C TNRC6A	2.78e-06	3	34	2	34108231
Pubmed	Gawky is a component of cytoplasmic mRNA processing bodies required for early Drosophila development.	TNRC6C TNRC6A	2.78e-06	3	34	2	16880270
Pubmed	The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers.	MUC16 FASN	2.78e-06	3	34	2	32698888
Pubmed	Expression of TNRC6 (GW182) Proteins Is Not Necessary for Gene Silencing by Fully Complementary RNA Duplexes.	TNRC6C TNRC6A	2.78e-06	3	34	2	31670606
Pubmed	An in situ hybridization study of perlecan, DMP1, and MEPE in developing condylar cartilage of the fetal mouse mandible and limb bud cartilage.	HSPG2 DMP1	5.56e-06	4	34	2	26428891
Pubmed	Two PABPC1-binding sites in GW182 proteins promote miRNA-mediated gene silencing.	TNRC6C TNRC6A	5.56e-06	4	34	2	21063388
Pubmed	The interactions of GW182 proteins with PABP and deadenylases are required for both translational repression and degradation of miRNA targets.	TNRC6C TNRC6A	5.56e-06	4	34	2	23172285
Pubmed	Structural basis of binding of P-body-associated proteins GW182 and ataxin-2 by the Mlle domain of poly(A)-binding protein.	TNRC6C TNRC6A	5.56e-06	4	34	2	20181956
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	HSPG2 DISP2 FAM89A FASN TNRC6C PHF12 ARSG PKD1	8.81e-06	1105	34	8	35748872
Pubmed	The C-terminal domains of human TNRC6A, TNRC6B, and TNRC6C silence bound transcripts independently of Argonaute proteins.	TNRC6C TNRC6A	1.94e-05	7	34	2	19383768
Pubmed	Functional dissection of the human TNRC6 (GW182-related) family of proteins.	TNRC6C TNRC6A	1.94e-05	7	34	2	19470757
Pubmed	A DDX6-CNOT1 complex and W-binding pockets in CNOT9 reveal direct links between miRNA target recognition and silencing.	TNRC6C TNRC6A	2.59e-05	8	34	2	24768540
Pubmed	miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT.	TNRC6C TNRC6A	4.15e-05	10	34	2	21984185
Pubmed	Large-scale proteomics and phosphoproteomics of urinary exosomes.	CMBL HSPG2 FASN DSG3 PGD ARPC1A PKD1	4.80e-05	1016	34	7	19056867
Pubmed	miRNA repression involves GW182-mediated recruitment of CCR4-NOT through conserved W-containing motifs.	TNRC6C TNRC6A	5.07e-05	11	34	2	21984184
Pubmed	Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation.	TNRC6C TNRC6A	8.38e-05	14	34	2	19716330
Pubmed	GW182 proteins directly recruit cytoplasmic deadenylase complexes to miRNA targets.	TNRC6C TNRC6A	9.66e-05	15	34	2	21981923
Pubmed	Trinucleotide repeat containing 6a (Tnrc6a)-mediated microRNA function is required for development of yolk sac endoderm.	TNRC6C TNRC6A	2.12e-04	22	34	2	22187428
Pubmed	Trinucleotide repeat containing 6c (TNRC6c) is essential for microvascular maturation during distal airspace sacculation in the developing lung.	TNRC6C TNRC6A	2.32e-04	23	34	2	28811219
Pubmed	UPF2 is a critical regulator of liver development, function and regeneration.	C2 FASN	2.53e-04	24	34	2	20657840
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	MUC16 FAT4 PHF12 FAM149A MIB1	3.66e-04	638	34	5	31182584
Pubmed	Autophagosomal Content Profiling Reveals an LC3C-Dependent Piecemeal Mitophagy Pathway.	HSPG2 FASN	4.81e-04	33	34	2	29149599
Pubmed	Human variation in alcohol response is influenced by variation in neuronal signaling genes.	DDO DMP1 PKD1	6.25e-04	171	34	3	20201926
Pubmed	High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions.	C2 HCP5 TRIM10	6.68e-04	175	34	3	19851445
Pubmed	Common genetic variation and the control of HIV-1 in humans.	HCP5 TRIM10	7.07e-04	40	34	2	20041166
Pubmed	Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1.	HSPG2 FASN	8.55e-04	44	34	2	31273033
Pubmed	A proteome-wide perspective on peroxisome targeting signal 1(PTS1)-Pex5p affinities.	PAOX DDO	8.55e-04	44	34	2	20178365
Cytoband	6p21.3	C2 HCP5 TRIM10	8.43e-04	250	34	3	6p21.3
GeneFamily	Ataxins\|Trinucleotide repeat containing	TNRC6C TNRC6A	3.09e-04	25	19	2	775
Coexpression	GSE18203_CTRL_VS_INTRATUMORAL_CPG_INJ_MC38_TUMOR_UP	C2 FASN TNRC6C TRIM10 MIB1 GGT5	2.06e-07	200	34	6	M7207
ToppCell	severe_COVID-19-HSPC\|World / disease group, cell group and cell class (v2)	CMBL HSPG2 DDO MAP7	9.79e-06	177	34	4	289f6aed6f054b04b01659434d8c8b467d1bf5dd
ToppCell	(2)_5-FU-(3)_LEPR+_perivascular_cells\|(2)_5-FU / Stress and Cell class	CMBL C2 PGD GGT5	1.46e-05	196	34	4	cc0a172de71d9a1a882c9e78652dae70e007d012
ToppCell	facs-Marrow-KLS-18m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADGRE4P FAM89A TRIM10	2.35e-04	158	34	3	0edd9b005875f9a4f5446f5d5161f8ba63860793
ToppCell	facs-Marrow-KLS-18m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADGRE4P FAM89A TRIM10	2.35e-04	158	34	3	9fd77ebdd1babf1c85a85d38d9a15858ab08bc84
ToppCell	frontal_cortex-Non-neuronal-leptomeningeal_cell-VLMC-VLMC_Spp1_Col15a1\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CMBL HSPG2 GGT5	2.39e-04	159	34	3	34c90711c5857cf6ada7b3acff99f1d48c7caf29
ToppCell	PND01-03-samps-Myeloid-Macrophage-CD163+_Macrophage\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	ADGRE4P PAOX TRIM10	2.44e-04	160	34	3	4480a7d6bd48d06b4e5196faac868f31ab7ed3ad
ToppCell	10x3'2.3-week_17-19-Hematopoietic-HSC/MPP_and_pro-HSC/MPP\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	CMBL DDO MAP7	2.53e-04	162	34	3	e73c644ce1db34f1d390878954e86fa0b3a455a1
ToppCell	3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	OLAH MUC16 KLK12	2.81e-04	168	34	3	de0b00bc405c898d08a06b2e585fb62c0ab9a66e
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	HSPG2 FAT4 FASN	2.96e-04	171	34	3	972fab891135bd755d5526cbc5a963200067b0a6
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	HSPG2 FAT4 FASN	2.96e-04	171	34	3	2a77ed79c6f2e700e789c80451a70ecb31639719
ToppCell	droplet-Marrow-BM_(NON-STC)-30m-Lymphocytic-plasma_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CMBL ADGRE4P FAM89A	3.01e-04	172	34	3	7295bf3ae21a61dd6bcfa0dfb7a37d0f3e8f94ab
ToppCell	ASK428-Immune-B_cell\|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq	MUC16 ARSG GGT5	3.11e-04	174	34	3	b5a7a612a515736cf3489afd0f6ad2054d54526f
ToppCell	severe_COVID-19-HSPC\|severe_COVID-19 / disease group, cell group and cell class (v2)	CMBL HSPG2 MAP7	3.11e-04	174	34	3	6d35bacf073537b272ff821e604c899fb9ce6a7c
ToppCell	ASK428-Immune-B_cell\|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq	MUC16 ARSG GGT5	3.17e-04	175	34	3	e0979e5795a49b4e5c9b88e7fe6b7bda7a413a6c
ToppCell	(00)_Basal-(2)_48hpi\|(00)_Basal / shred by cell type and Timepoint	CMBL MUC16 PGD	3.22e-04	176	34	3	0f6770296d7fa453ffbf6ca6d5fdebc888f6eb60
ToppCell	3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Progenitor_MEMP\|lymph-node_spleen / Manually curated celltypes from each tissue	CMBL HSPG2 MAP7	3.22e-04	176	34	3	23a8ec42ebd42c539865a12d09773af90f3f8848
ToppCell	droplet-Liver-hepatocytes-3m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 DISP2 FAT4	3.27e-04	177	34	3	8ef41ee5d63737b810ad7371b0437625e7e1badf
ToppCell	droplet-Marrow-BM-1m-Lymphocytic-plasma_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CMBL ADGRE4P C2	3.27e-04	177	34	3	26bad614560609d318bfc9c235a698bca4e1c22c
ToppCell	control-Others-CD34+_GATA2+_cells\|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CMBL HSPG2 MAP7	3.33e-04	178	34	3	2120bd3e099b0b271bf079db9827a2f3eee2f909
ToppCell	PND03-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial-Mesothelial_G2M\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MUC16 C2 ZAN	3.33e-04	178	34	3	c77a1d1a9aef0ab51b4408b9e84f201219788ca2
ToppCell	390C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)\|390C / Donor, Lineage, Cell class and subclass (all cells)	MUC16 KLK12 GGT5	3.33e-04	178	34	3	fce60ce6b662f1bdaa3b4da43800c6c22fe89533
ToppCell	390C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	MUC16 KLK12 GGT5	3.33e-04	178	34	3	b19c906e067b07eadfd68934d9330b447e24c708
ToppCell	PBMC-Mild-Hematopoietic-HSPC\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.38e-04	179	34	3	2f690f933bf6b99abeb31766e0b22bdbe36c1ba0
ToppCell	COVID-19_Mild-Hematopoietic_SC-HSPC\|COVID-19_Mild / Disease group, lineage and cell class	CMBL HSPG2 MAP7	3.38e-04	179	34	3	19fcf48f5e02e4cb2b328efb4502f337e1282f72
ToppCell	PBMC-Mild-Hematopoietic-HSPC-HSPC-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.38e-04	179	34	3	4bb2debfc9e9f258cd38e797ef160bd440aad6af
ToppCell	severe-Others-CD34+_GATA2+_cells\|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CMBL HSPG2 MAP7	3.38e-04	179	34	3	dd789a1b7327d6f9ed5272f3eb54bd43f7ae8d78
ToppCell	PBMC-Mild-Hematopoietic-HSPC-HSPC\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.38e-04	179	34	3	3e2c937369b8190fd5d5a31689d029e6e89fb5e2
ToppCell	COVID-19_Mild-Hematopoietic_SC\|COVID-19_Mild / Disease group, lineage and cell class	CMBL HSPG2 MAP7	3.38e-04	179	34	3	50a073166e34bcfa52a62c4dafb3aef724e0fa8e
ToppCell	systemic_lupus_erythematosus-treated-Hematopoietic-progenitor_cell\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CMBL FAT4 MAP7	3.44e-04	180	34	3	2694f5deaed551c53e74d8a9fbd41d3734bb9f37
ToppCell	systemic_lupus_erythematosus-treated-Hematopoietic-progenitor_cell-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CMBL FAT4 MAP7	3.44e-04	180	34	3	ef0de602fc8ccfd32a06978ac0100afe0ce1beeb
ToppCell	PBMC-Mild-Hematopoietic-HSPC-HSPC\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	CMBL HSPG2 MAP7	3.50e-04	181	34	3	54a19cf6a3b752e2391feb8b316bebee0e602d17
ToppCell	PBMC-Mild-Hematopoietic-HSPC\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	CMBL HSPG2 MAP7	3.50e-04	181	34	3	5b84625b1d3737708001b64f6da9360330d39a27
ToppCell	droplet-Liver-hepatocytes-3m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 DISP2 FAT4	3.50e-04	181	34	3	4df7972f88117108698efd06b124b232f8588981
ToppCell	PBMC-Mild-Hematopoietic-HSPC-HSPC-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CMBL HSPG2 MAP7	3.50e-04	181	34	3	e7f7b519c2a01c15f26df11ec9b434c0d1630c7a
ToppCell	droplet-Liver-hepatocytes-3m-Endothelial\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 DISP2 FAT4	3.50e-04	181	34	3	cbb530566893281289026bfd93adf721decd4ca3
ToppCell	PBMC-Control-Hematopoietic-HSPC-HSPC-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CMBL HSPG2 MAP7	3.55e-04	182	34	3	6497eeafb2b137e70261ec0314782831892a940d
ToppCell	Control-Hematopoietic_SC-HSPC\|Control / Disease group, lineage and cell class	CMBL HSPG2 MAP7	3.55e-04	182	34	3	14e347c0e6444410f1948851407bb18c706569f4
ToppCell	Control-Hematopoietic_SC\|Control / Disease group, lineage and cell class	CMBL HSPG2 MAP7	3.55e-04	182	34	3	43243c6bae2ac7fa3fd1f193a17f61ee4d938ea9
ToppCell	PBMC-Control-Hematopoietic-HSPC-HSPC\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.55e-04	182	34	3	d0ebf2f0d5370458ab81485a0017c311077133d5
ToppCell	PBMC-Control-Hematopoietic-HSPC\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.55e-04	182	34	3	918286422b3eab32d962b49aa07b1b9512e51d9d
ToppCell	PBMC-Control-Hematopoietic-HSPC\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CMBL HSPG2 MAP7	3.55e-04	182	34	3	bd1626261803324084fafca2f6665b50854e7fae
ToppCell	PBMC-Control-Hematopoietic-HSPC-HSPC-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.55e-04	182	34	3	2a6d1246bfb5899a0861c7f2f8fb9b43b0df8acc
ToppCell	PBMC-Control-Hematopoietic-HSPC-HSPC\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CMBL HSPG2 MAP7	3.55e-04	182	34	3	0d9b8c900da8cbae9cde72aecd4026b1ac2bbd67
ToppCell	COVID-19_Severe-Hematopoietic_SC-HSPC\|COVID-19_Severe / Disease group, lineage and cell class	CMBL HSPG2 MAP7	3.61e-04	183	34	3	4146b1c0e5f76d25226745abfa28f77127a444fc
ToppCell	COVID-19_Severe-Hematopoietic_SC\|COVID-19_Severe / Disease group, lineage and cell class	CMBL HSPG2 MAP7	3.61e-04	183	34	3	92aab7ce65aca17988bc2add4ff9fb8384e2c21b
ToppCell	3'_v3-bone_marrow-Hematopoietic_Erythro-Mega-Erythrocytic_early\|bone_marrow / Manually curated celltypes from each tissue	CMBL MAP7 TRIM10	3.61e-04	183	34	3	d43ba3fbbd9132125fa2b7ea0891a2c577974f14
ToppCell	3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Progenitor_pre-Lymphocytic-T\|lymph-node_spleen / Manually curated celltypes from each tissue	DDO MAP7 GGT5	3.61e-04	183	34	3	6c55fd737ed31f5b1aa41dc4dba7240521c19022
ToppCell	PBMC-Severe-Hematopoietic-HSPC\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.67e-04	184	34	3	a6169613c6493b947a176493f542368bfa935dab
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CMBL HSPG2 MAP7	3.67e-04	184	34	3	51d0447699e3b8f01abbde83f26b748bc9f3c723
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.67e-04	184	34	3	cc01c19180861f491a8dc16d60fabd1215fc4525
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CMBL HSPG2 MAP7	3.67e-04	184	34	3	f7b0bb45a9055ab34e98b251217f6ec38c75ca22
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CMBL HSPG2 MAP7	3.67e-04	184	34	3	492c680f0769ba4e651d09c2e8e5d5d271ed08aa
ToppCell	PBMC-Severe-Hematopoietic-HSPC\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CMBL HSPG2 MAP7	3.67e-04	184	34	3	26edbf84216538b80f1ffcc079ee6e385a71fbf9
ToppCell	metastatic_Brain-Endothelial_cells-Stalk-like_ECs\|metastatic_Brain / Location, Cell class and cell subclass	HSPG2 DISP2 GGT5	3.73e-04	185	34	3	ad52970e88e8947ef256095bd4b40229b912d58a
ToppCell	metastatic_Brain-Myeloid_cells-Alveolar_Mac\|metastatic_Brain / Location, Cell class and cell subclass	OLAH C2 PGD	3.79e-04	186	34	3	9270e04c61b743874424a5935537b62e7d89c461
ToppCell	3'_v3-blood-Hematopoietic_progenitors-Progenitor_Erythro-Mega\|blood / Manually curated celltypes from each tissue	CMBL HSPG2 MAP7	3.79e-04	186	34	3	59c115bbbb4bca4ad80be1809d8a0422b8438ea3
ToppCell	3'_v3-bone_marrow-Hematopoietic_Erythro-Mega\|bone_marrow / Manually curated celltypes from each tissue	CMBL MAP7 TRIM10	3.79e-04	186	34	3	9ff3c30b1728707bb8f9422941333fe3b2c430f4
ToppCell	(8)_CD34_progenitor\|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)	CMBL HSPG2 MAP7	3.79e-04	186	34	3	e69a986b8618effd61875fda528a2e44aab11868
ToppCell	(8)_CD34_progenitor\|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)	CMBL HSPG2 MAP7	3.79e-04	186	34	3	943c604a7cd873faf510096d094100512ba2d6bc
ToppCell	10x3'2.3-week_17-19-Hematopoietic-HSC/MPP_and_pro-CMP\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	CMBL MAP7 ZAN	3.85e-04	187	34	3	624e663d5ddc6b8fefbd0e3207bf1928c2478b7b
ToppCell	Healthy-HSPC\|World / disease group, cell group and cell class	CMBL HSPG2 MAP7	3.85e-04	187	34	3	8cd9e5499e5c2b2321ecbcf780df37fe0f165ac9
ToppCell	(2)_5-FU-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)\|(2)_5-FU / Stress and Cell class	CMBL C2 GGT5	3.85e-04	187	34	3	6bbf0f7fe203274dae8d582652f35cd3187c0065
ToppCell	COVID-19_Severe-HSPC\|COVID-19_Severe / disease group, cell group and cell class	CMBL HSPG2 MAP7	3.97e-04	189	34	3	96015439971e2e5b8d6294ca5a6b873c7774e925
ToppCell	moderate-Lymphoid-NK\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	HSPG2 FAT4 GGT5	3.97e-04	189	34	3	22a19365782003c18ec8dddcdbfdaa82c4e330f6
ToppCell	COVID-19_Severe-HSPC\|World / disease group, cell group and cell class	CMBL HSPG2 MAP7	3.97e-04	189	34	3	555c0b13f1508b9e3712b36d77144e73e828bc76
ToppCell	Healthy-HSPC\|Healthy / disease group, cell group and cell class	CMBL HSPG2 MAP7	3.97e-04	189	34	3	214b225effc40ca1b83dd8052f2a7b80b65d4938
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FASN MAP7 FAM149A	4.15e-04	192	34	3	cc9911e182a289779a2612bc213daae5607689e7
ToppCell	(1)_Control_(PBS)-(3)_LEPR+_perivascular_cells\|(1)_Control_(PBS) / Stress and Cell class	CMBL C2 GGT5	4.15e-04	192	34	3	40f380f5f0bed63a7404be050838ebd01ef08987
ToppCell	3'_v3-bone_marrow-Hematopoietic_progenitors-Progenitor_Erythro-Mega\|bone_marrow / Manually curated celltypes from each tissue	CMBL HSPG2 MAP7	4.15e-04	192	34	3	cbc304c704e8524eee24a1619d0fbb2cf96c4976
ToppCell	PCW_05-06-Epithelial-Epithelial_airway-epi_proximal_progenitor2_(4)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	MUC16 MAP7 FAM149A	4.15e-04	192	34	3	c15841f35e24d6ef6ce2a9a6dc62e66efdc3d9d5
ToppCell	390C-Myeloid-Macrophage-FABP4+_Macrophage_2\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	C2 DDO FAM89A	4.22e-04	193	34	3	c9cf5a661294a947d06d53d18d47362c0e0b6ef5
ToppCell	(2)_5-FU-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)\|World / Stress and Cell class	CMBL C2 GGT5	4.22e-04	193	34	3	f31398dad5321a7bcb27e208bd73630e9756e897
ToppCell	PCW_05-06-Epithelial-Epithelial_neuroendo\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	KLK12 MAP7 FAM149A	4.22e-04	193	34	3	aa10924b203c71e65fdbd2b90ba131dbd362d8b1
ToppCell	erythropoietic-CD34+_Pro-erythroblast\|World / Lineage and Cell class	CMBL HSPG2 MAP7	4.28e-04	194	34	3	cd12d01f6f2f12bbc33ed523bc678d3965074974
ToppCell	Bronchial_Biopsy-Immune-Luminal_Macrophages\|Immune / Tissue, Lineage and Cell class of Lung Cells from 10X	C2 FAM89A PGD	4.35e-04	195	34	3	6800c17026ec6c56132bf4664b8fcd74d7836579
ToppCell	AT2_cells-Donor_06\|World / lung cells shred on cell class, cell subclass, sample id	C2 FASN GGT5	4.35e-04	195	34	3	b0cea3f4e59635913d243612f2e8cf4c7b34e726
ToppCell	367C-Myeloid-Macrophage-FABP4+_Macrophage\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	C2 FAM89A PGD	4.35e-04	195	34	3	f664fe18856065baaa2837fc82ea946e45f6fcc3
ToppCell	cellseq2-Epithelial-Epithelial_Glandular-Mucous\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CMBL MUC16 KLK12	4.41e-04	196	34	3	98e3f9c886063def16c74ab75fc81511a7872f1c
ToppCell	10x5'v1-week_14-16-Hematopoietic-HSC/MPP_and_pro-CMP\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	CMBL MAP7 ZAN	4.41e-04	196	34	3	f9a7d62684435f7c8a1205e2d0b2af0f6104a2dd
ToppCell	10x3'2.3-week_12-13-Hematopoietic\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	CMBL MAP7 TRIM10	4.41e-04	196	34	3	05b437af66cb43ba098ea93a02dc2f7430bf8c1b
ToppCell	cellseq2-Epithelial-Epithelial_Glandular-Mucous-Mucous\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CMBL MUC16 KLK12	4.41e-04	196	34	3	357a5440aeebf69688bfe9fbc8585950ad00906b
ToppCell	erythropoietic\|World / Lineage and Cell class	CMBL FAM89A MAP7	4.48e-04	197	34	3	a52546cebc222050c970e04cec97e4f48ab8fe10
ToppCell	erythropoietic-Basophilic_Erythroblast\|World / Lineage and Cell class	CMBL FAM89A MAP7	4.54e-04	198	34	3	b3db4db02c0e659163cefb3d83f53e4940cc04bf
ToppCell	COVID-19-COVID-19_Mild-Others-HSPC\|COVID-19_Mild / Disease, condition lineage and cell class	CMBL HSPG2 MAP7	4.61e-04	199	34	3	0230103c37ae3aff58240739b89f2c36b1e39a69
ToppCell	COVID-19-COVID-19_Severe-Others-HSPC\|COVID-19_Severe / Disease, condition lineage and cell class	CMBL HSPG2 MAP7	4.61e-04	199	34	3	25de67b6c9c8d6bb9a538e071a40ef865906c95d
ToppCell	Control-Control-Others-HSPC\|Control / Disease, condition lineage and cell class	CMBL HSPG2 MAP7	4.61e-04	199	34	3	b71169be0d916b2ed139a3122d78bb154c71edb4
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW19-Neuroepithelial-Proteoglycan-expressing_cell\|GW19 / Sample Type, Dataset, Time_group, and Cell type.	C2 FAM89A GGT5	4.68e-04	200	34	3	aafe594c88710f8c53d59667cdac5035e08f5511
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW19-Neuroepithelial\|GW19 / Sample Type, Dataset, Time_group, and Cell type.	C2 FAM89A GGT5	4.68e-04	200	34	3	a6f0f5f644b7262878b0b9d4d90ee407c4124dd9
Drug	oxaloacetate	PHKA2 C2 DDO GOT1L1 PGD GGT5	4.40e-07	198	34	6	CID000000970
Drug	Lisinopril [83915-83-7]; Up 200; 9uM; HL60; HT_HG-U133A	HSPG2 FASN MAP7 DSG3 FAM149A	1.05e-05	197	34	5	2371_UP
Drug	tosyl fluoride	FASN GGT5	1.30e-05	4	34	2	CID000009965
Drug	dimethyl itaconate	C2 FASN	1.30e-05	4	34	2	CID000069240
Drug	hydroxyl radicals	CMBL PAOX OLAH C2 DDO GOT1L1 FASN APOBEC4 ARSG GGT5	1.73e-05	1341	34	10	CID000000961
Drug	formic acid ethyl ester	C2 DSG3	2.16e-05	5	34	2	CID000008025
Drug	pyruvic acid	PHKA2 C2 GOT1L1 FASN PGD GGT5	3.48e-05	424	34	6	CID000001060
Drug	C04226	C2 PGD	6.03e-05	8	34	2	CID000151255
Drug	iminoaspartate	DDO GOT1L1	6.03e-05	8	34	2	CID000000796
Drug	ammonia	PAOX C2 DDO GOT1L1 APOBEC4 PKD1	9.58e-05	509	34	6	CID000000222
Drug	Br-coeleneterazine	C2 DSG3	9.67e-05	10	34	2	CID005288010
Drug	Fc13	C2 DMP1	1.18e-04	11	34	2	CID000006392
Drug	glyoxylate	PAOX C2 DDO PGD	1.34e-04	176	34	4	CID000000760
Drug	anisylamine	C2 DSG3	1.42e-04	12	34	2	CID000075452
Drug	Diltiazem hydrochloride [33286-22-5]; Up 200; 8.8uM; PC3; HT_HG-U133A	PAOX SPIDR MAP7 FAM149A	1.94e-04	194	34	4	6710_UP
Drug	Lidocaone hydrochloride [73-78-9]; Up 200; 14.8uM; PC3; HT_HG-U133A	PAOX KLK12 DMP1 DSG3	2.02e-04	196	34	4	4596_UP
Drug	Ethambutol dihydrochloride [1070-11-7]; Up 200; 14.4uM; PC3; HT_HG-U133A	PAOX KLK12 SPIDR DMP1	2.06e-04	197	34	4	4001_UP
Drug	Guanadrel sulfate [22195-34-2]; Down 200; 7.6uM; HL60; HT_HG-U133A	HSPG2 SPIDR DMP1 FAM149A	2.10e-04	198	34	4	2575_DN
Drug	Chlorogenic acid [327-97-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A	PAOX HSPG2 FAT4 SPIDR	2.10e-04	198	34	4	4142_UP
Drug	Lorglumide sodium salt [97964-56-2]; Up 200; 8.4uM; HL60; HT_HG-U133A	PAOX KLK12 SPIDR DMP1	2.18e-04	200	34	4	3079_UP
Drug	AC1Q6HGX	C2 PGD	2.25e-04	15	34	2	CID000000600
Drug	propylene carbonate	C2 DSG3	2.56e-04	16	34	2	CID000007924
Drug	phosphoglycolate	C2 PGD PKD1	3.27e-04	90	34	3	CID000000529
Drug	o-cresol	C2 DDO	3.64e-04	19	34	2	CID000000335
Drug	phytanic acid	PAOX C2 DDO	3.95e-04	96	34	3	CID000026840
Drug	kg y	C2 DSG3	4.04e-04	20	34	2	CID011963536
Drug	T 50	PAOX DSG3	4.47e-04	21	34	2	CID000468848
Drug	NSC316735	PHKA2 C2 PGD	4.72e-04	102	34	3	CID000000422
Drug	glycogen	PHKA2 C2 FASN PGD GGT5	4.76e-04	443	34	5	CID000439177
Drug	N,N-dimethylacrylamide	HSPG2 DSG3	4.91e-04	22	34	2	CID000017587
Drug	retene	CMBL PGD	5.85e-04	24	34	2	ctd:C447880
Drug	AC1L1A5Z	C2 FASN PGD	6.04e-04	111	34	3	CID000000850
Drug	Pf-5	FASN PHF12	6.88e-04	26	34	2	CID000024295
Drug	POCA	C2 FASN	6.88e-04	26	34	2	CID000054217
Drug	benzo(b)fluorene	CMBL PGD	7.42e-04	27	34	2	ctd:C041512
Drug	oxygen	PAOX C2 DDO GOT1L1 DSG3	8.16e-04	499	34	5	CID000000977
Drug	Procion Red HE-3B	DSG3 PGD	8.57e-04	29	34	2	CID005464465
Drug	k Pa	C2 PGD	9.17e-04	30	34	2	CID004369480
Drug	3-aminopropanal	PAOX DDO	9.17e-04	30	34	2	CID000000075
Drug	2-keto-3-deoxy-6-phosphogluconate	C2 PGD	9.17e-04	30	34	2	CID000000046
Drug	aspartate	C2 DDO GOT1L1 ARPC1A GGT5	9.64e-04	518	34	5	CID000000424
Drug	hypotaurine	C2 DSG3	9.80e-04	31	34	2	CID000107812
Drug	pyridoxal 5'-phosphate	PHKA2 C2 GOT1L1 FASN	1.02e-03	301	34	4	CID000001051
Drug	AC1Q6RZK	C2 PGD	1.04e-03	32	34	2	CID000000153
Drug	V O2	C2 DSG3	1.11e-03	33	34	2	CID000082849
Drug	4-nitrocatechol	DDO ARSG	1.11e-03	33	34	2	CID003505109
Drug	hypusine	PAOX GGT5	1.18e-03	34	34	2	CID000065396
Drug	isovalerate	MAP7 PKD1 TNRC6A	1.26e-03	143	34	3	CID000010430
Drug	sodium pyruvate	C2 DSG3	1.40e-03	37	34	2	CID010154024
Drug	CETTD	C2 FASN	1.40e-03	37	34	2	CID000150912
Drug	acrylyl-coenzyme A	C2 FASN	1.40e-03	37	34	2	CID000439340
Drug	AC1L9GQC	PGD TNRC6A	1.40e-03	37	34	2	CID000444689
Drug	oxamate	PAOX C2	1.47e-03	38	34	2	CID000000974
Drug	fructose-1,6-diphosphate sodium salt	PHKA2 C2 PGD	1.47e-03	151	34	3	CID000000718
Disease	Dermatitis, Irritant	C2 TRIM10	4.62e-05	9	34	2	C0162823
Disease	platelet aggregation	C2 HCP5	1.24e-03	45	34	2	GO_0070527
Disease	human papilloma virus infection, oropharynx cancer	PAOX HCP5	1.71e-03	53	34	2	EFO_0001668, EFO_1001931
Disease	susceptibility to cold sores measurement	MUC16 HCP5	2.56e-03	65	34	2	EFO_0008402

Protein segments in the cluster

Peptide	Gene	Start	Entry
GGIWHSVLHSFISGV	APOBEC4	191	Q8WW27
WGHITEQSGTHGYLG	GOT1L1	341	Q8NHS2
SGNGLGWFHISEHSG	FAT4	516	Q6V0I7
GWFHISEHSGLVTTG	FAT4	521	Q6V0I7
GSEGGWSTEGCSHVH	ADGRE4P	146	Q86SQ3
HTNWTGHGGTVSSSS	PGD	466	P52209
VTGIIGKWHLGHHGS	ARSG	131	Q96EG1
SHHSSLSWKGRGGPG	DISP2	1356	A7MBM2
SGTGGWVHGVSFSAS	ARPC1A	201	Q92747
HGIAESDWHLEGSGG	HSPG2	4181	P98160
GSEGTIHQWGIEGAH	DSG3	661	P32926
MWHGSTGGTTGDTHV	MUC16	3346	Q8WXI7
SWGGSLHGSPSIHSA	MAP7	161	Q14244
GSHTPTGAHTSWSGS	FAM149A	236	A5PLN7
AGTECHVSGWGITNH	KLK12	136	Q9UKR0
SGGTFTLSHGWAPGS	C2	31	P06681
EHWVGGGSDGESSHG	DMP1	191	Q13316
WRGGDSSSHPLVSGH	HCP5	91	Q6MZN7
HGHGGWTDGMFETLT	MIB1	266	Q86YT6
HGSGGISVHWGTALE	DDO	306	Q99489
AWGHGTGTSHVSVLG	GGT5	381	P36269
RGTHTGVWVGVSGSE	FASN	101	P49327
GGGSTHFAKWGQDTH	OLAH	36	Q9NV23
TGTSSSDSGGHHIGW	PHKA2	1046	P46019
TGWGRGSGTTAHVGI	PKD1	3126	P98161
GGVVEVGAHWIHGPS	PAOX	61	Q6QHF9
GNIHSGAWGHPSRST	TNRC6C	321	Q9HCJ0
HSASGGGASGGWRHL	FAM89A	36	Q96GI7
GSGAGWEGTALLHHG	PHF12	936	Q96QT6
IGIVGFCWGGTAVHH	CMBL	126	Q96DG6
GVATTGTAWTHGHKE	SPIDR	436	Q14159
AHTGITGGRHTWVVS	TRIM10	356	Q9UDY6
GTGTWLHYTSGVGTG	PPIP5K2	986	O43314
HGSSTGPWGFSHGAI	TNRC6A	306	Q8NDV7
VQTSGDGGHWALGHK	ZAN	386	Q9Y493